Long-term benefit of fluorescent cystoscopy-assisted transurethral resection in patients with non-muscle invasive bladder cancer is dependent on quality of surgery

2017 ◽  
Vol 16 (5) ◽  
pp. e2236
Author(s):  
A. Rolevich ◽  
A. Minich ◽  
A. Zhegalik ◽  
A. Mokhort ◽  
V. Vasilevich ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transurethral Resection ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Quality Of Surgery ◽  
Muscle Invasive ◽  
Term Benefit

scholarly journals 377 Global Recruitment for The RESECT Study (Transurethral Resection and Single-Instillation Intravesical Chemotherapy Evaluation in Bladder Cancer Treatment): An International Observational Cohort Study Aiming to Improve the Quality of Surgery for Non-Muscle Invasive Bladder Cancer

2021 ◽  
Vol 108 (Supplement_2) ◽  
Author(s):  
A Light ◽  
K Gallagher ◽  
N Bhatt ◽  
K Clement ◽  
M a Kulkarni ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Transurethral Resection ◽  
Statistical Power ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Mailing Lists ◽  
Quality Of Surgery ◽  
Muscle Invasive

Abstract Introduction Non-muscle invasive bladder cancer (NMIBC) can be curatively treated with ‘good quality’ transurethral resection of the bladder tumour (TURBT). However, despite evidence-based international guidelines, there is anecdotal evidence that practice varies widely, and this may affect oncological outcomes. Launching in 2020, RESECT aims to measure and report variation in TURBT quality globally, and determine if outcome reporting improves outcomes. Method RESECT was advertised internationally through social media, mailing lists, websites, and in person. Collaborators at each registered site will collect data about current practice and the experience of local TURBT surgeons. The primary outcome is the rate of achievement of key TURBT quality indicators. Results As of August 27, 508 collaborators have registered to participate. Collaborators represent 321 centres from 54 countries, with the highest number from the United Kingdom (54.5%), Spain (5.9%), and Argentina (3.7%). 51.2% are trainees, 29.9% consultants, and 17.5% medical students. Based on current registrations, patient recruitment will far exceed initial projections and considerably improve statistical power. Conclusions RESECT has attracted a large number of collaborators globally and from all training levels. Therefore, the RESECT study has the potential to improve the quality of TURBT surgery across the world.

Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer

2015 ◽  
Vol 93 (3) ◽  
pp. S23
Author(s):  
K.S. Mak ◽  
A.B. Smith ◽  
A. Eidelman ◽  
R.H. Clayman ◽  
J.S. Cheng ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Long Term Survivors

scholarly journals The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long-Term Followup

2018 ◽  
Vol 5 (4) ◽  
pp. 305-310
Author(s):  
Stanley A. Yap ◽  
Neil Pugashetti ◽  
Thenappan Chandrasekar ◽  
Marc A. Dall’Era ◽  
Christopher P. Evans ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Transurethral Resection ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Quality of life in long-term survivors of muscle-invasive bladder cancer.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 319-319
Author(s):  
Kimberley S. Mak ◽  
Angela Smith ◽  
Alec Eidelman ◽  
Rebecca Helen Clayman ◽  
Jed-Sian Cheng ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bladder Cancer ◽  
Bowel Function ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Trimodality Therapy ◽  
Muscle Invasive ◽  
Eortc Qlq

319 Background: Health-related quality of life (QOL) is not well-studied in survivors of muscle-invasive bladder cancer (MIBC). This cross-sectional multi-institutional study compared long-term QOL in MIBC patients treated with bladder-sparing trimodality therapy (TMT) vs. radical cystectomy (RC). Methods: Patients with non-metastatic cT2-T4 MIBC, diagnosed in 1990-2011 and disease-free for ≥2 years were identified. A questionnaire using validated general and disease-specific QOL instruments was administered (score ranges: 0-100). Results: Of 226 eligible patients, 173 returned the questionnaire for a response rate of 77%. Sixty-four received TMT and 109 RC (89 with ileal conduit and 18 with neobladder diversions). The median time from diagnosis to questionnaire was 9 vs. 6 years, respectively (p=0.009). Comparing TMT to RC, there was no significant difference in age at diagnosis or questionnaire, gender, smoking, clinical stage or comorbidities. On univariable analysis (UVA), patients who received TMT had significantly better general QOL than patients who received RC by 4.8 points on the EQ-5D 3L and 7.4 points on the EORTC QLQ-C30 (Table). On multivariable analysis (MVA), adjusting for age, time from diagnosis, year of treatment, gender and comorbidities, patients who received TMT had significantly better general QOL by an average 6-7 points. On MVA, TMT was associated with significantly better bowel function by an average 4.5 points on the EPIC bowel function subscale, but with no difference in bowel bother. Urinary QOL was equivalent between groups, as measured by the EORTC QLQ-BLM30. Conclusions: While both TMT and RC provide good long-term outcomes, TMT appears to be associated with higher general QOL and bowel function compared to RC. [Table: see text]

Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer

2016 ◽  
Vol 96 (5) ◽  
pp. 1028-1036 ◽  
Author(s):  
Kimberley S. Mak ◽  
Angela B. Smith ◽  
Alec Eidelman ◽  
Rebecca Clayman ◽  
Andrzej Niemierko ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Long Term Survivors

Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer

2021 ◽  
pp. 1-9
Author(s):  
Emmanuelle Fabiano ◽  
Catherine Durdux ◽  
Bertrand Dufour ◽  
Arnaud Mejean ◽  
Nicolas Thiounn ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Long Term Outcomes ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document